Pfizer Pre-Paid Expenses 2010-2024 | PFE

Pfizer pre-paid expenses from 2010 to 2024. Pre-paid expenses can be defined as a current asset created by prepayment of costs and expenses for which the benefits will occur at a future date.
  • Pfizer pre-paid expenses for the quarter ending September 30, 2024 were $M, a NAN% increase year-over-year.
  • Pfizer pre-paid expenses for 2023 were $0B, a NAN% decline from 2022.
  • Pfizer pre-paid expenses for 2022 were $0B, a NAN% decline from 2021.
  • Pfizer pre-paid expenses for 2021 were $0B, a NAN% decline from 2020.
Pfizer Annual Pre-Paid Expenses
(Millions of US $)
2023 $
2022 $
2021 $
2020 $
2019 $
2018 $
2017 $
2016 $
2015 $
2014 $
2013 $
2012 $
2011 $
2010 $
2009 $6,962
Pfizer Quarterly Pre-Paid Expenses
(Millions of US $)
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30
2020-03-31
2019-12-31
2019-09-30
2019-06-30
2019-03-31
2018-12-31
2018-09-30
2018-06-30
2018-03-31
2017-12-31
2017-09-30
2017-06-30
2017-03-31
2016-12-31
2016-09-30
2016-06-30
2016-03-31
2015-12-31
2015-09-30
2015-06-30
2015-03-31
2014-12-31
2014-09-30
2014-06-30
2014-03-31
2013-12-31
2013-09-30
2013-06-30
2013-03-31
2012-12-31
2012-09-30
2012-06-30
2012-03-31
2011-12-31
2011-09-30
2011-06-30
2011-03-31
2010-12-31
2010-09-30
2010-06-30
2010-03-31
2009-12-31 $6,962
2009-09-30 $4,679
2009-06-30 $5,310
2009-03-31 $5,055
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $148.702B $58.496B
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $790.248B 81.85
Novo Nordisk (NVO) Denmark $489.545B 35.30
Johnson & Johnson (JNJ) United States $373.278B 15.14
AbbVie (ABBV) United States $308.242B 16.23
Merck (MRK) United States $254.810B 16.93
Novartis AG (NVS) Switzerland $215.989B 14.36
AstraZeneca (AZN) United Kingdom $200.887B 17.90
Sanofi (SNY) $128.465B 11.64
Innoviva (INVA) United States $1.259B 10.48